The plasma levels of fibronectin in patients with ischemic heart failure

Authors

  • S. V. Fedorov

DOI:

https://doi.org/10.14739/2310-1210.2014.6.35654

Keywords:

Heart Failure, Fibronectin

Abstract

The main element of heart failure progression is extracellular matrix condition, where the fibronectin is an important component.

Aim.To investigate the plasma levels of fibronectinin patients with ischemic heart failure.

Methods and results. The identification of the plasma levels of fibronectin’s concentration was made by ELISA method.

Conclusion. The fibronectin plasma levels are higher in patients with II-III HF (NYHA) and at presence of atrial fibrillation. The main important factors, which have influence for fibronectin concentration, are endogenous intoxication, left atrium size and end-systolic volume of left ventricle.

References

Deaton, C., Froelicheer, E., Wu, L.,et al. (2011).The Global Burden of Cardiovascular Disease. Journal of Cardiovascular Nursing,26, S5–S14.

McMurrey, J., Adamopoulus, S., Anker S.,et al. (2012).ESC Guidelines for the diagnosis and treatmentof acute and chronic heart failure 2012. European Heart Journal, 33, 1787–1847.doi: 10.1093/eurheartj/ehs104.

Stewart, S., Jenkins, A., Buchan, S.,et al. (2002). The current cost of heart failure to the national health service in UK. Eur. Heart Fail., 4, 361–371.doi: 10.1016/S1388-9842(01)00198-2.

Jordan, A., Roldan, V.,Garcıa, M.,et al. (2007). Matrix metalloproteinase-1 and its inhibitor, TIMP-1, insystolic heart failure: relation to functional data andprognosis. J. Intern. Med., 262, 385–392.

Aziz-Seible,R.,&Casey, C. (2011). Fibronectin: Functional character and role in alcoholic liver disease. World J. Gastroent., 17, 2482–2499.doi: 10.3748/wjg.v17.i20.2482.

Yang, D.C., Ma, S.T., &Tan, Y. (2010). Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure.Cardiology, 116 (2), 133–141.doi: 10.1159/000317245.

Kuriata, A. V., Miroshnichenko, A. A., &Mitrohina, O. S. (2010) The influence of medicament therapy of chronic heart failure in patients with preserved ejection fraction for functional status of kidney, level of a1-acid glycoprotein and fibronectin.SuchasniMedychniTekhnologii, 3, 52–57.

Moore, K.J., &Fisher, E.A. (2012). The double-edged sword of fibronectinin atherosclerosis. EMBO Mol. Med., 4, 561–563.

Downloads

How to Cite

1.
Fedorov SV. The plasma levels of fibronectin in patients with ischemic heart failure. Zaporozhye medical journal [Internet]. 2014Dec.8 [cited 2024Apr.26];16(6). Available from: http://zmj.zsmu.edu.ua/article/view/35654

Issue

No. 6 (2014): Zaporozhye medical journal

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)